GlaxoSmithKline has announced that its asthma therapy Relvar Ellipta has been approved for a broader indication in Europe.
The European Commission has approved a label update for the use of once-daily Relvar Ellipta among patients whose asthma is already adequately controlled on both an inhaled corticosteroid (ICS) and long-acting beta 2-agonist (LABA).
Relvar Ellipta is an ICS/LABA combination therapy developed in partnership with Innoviva, and is administered via a single inhaler, the Ellipta.
Clinical trial data has shown that patients with adequately controlled asthma were able to switch to once-daily Relvar Ellipta therapy without compromising their lung function, with safety data shown to be consistent with known trends.
Jonathan Sweeting, senior vice-president and head of GlaxoSmithKline's global respiratory franchise, said: "Patients with asthma can continue to experience symptoms despite being adequately controlled and these symptoms can impact their lives. This label update gives doctors the option of switching appropriate patients from their current ICS/LABA to once-daily Relvar Ellipta."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.